Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 3(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01297699Phase 3Completed

Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease)

Role: collaborator

NCT02204332Phase 2Terminated

Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment

Role: collaborator

NCT01314859Phase 3Withdrawn

Nifedipine Treatment in Preterm Labor

Role: collaborator

NCT02201368Phase 3Withdrawn

Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects

Role: collaborator

All 4 trials loaded